Clinical translation of multipotent mesenchymal stromal cells in transplantation

Seminars in Nephrology

Volumn 34, Issue 4, 2014, Pages 351-364

  Leuning, Daniëlle G ^a   Reinders, Marlies E J ^a   de Fijter, Johannes W ^a   Rabelink, Ton J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Immunomodulation; Kidney transplantation; Mesenchymal stromal cells; Renal disease; Repair

Indexed keywords

5' NUCLEOTIDASE; ANGIOPOIETIN 1; CD34 ANTIGEN; CD45 ANTIGEN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEPREDNISONE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; IMMUNOSUPPRESSIVE AGENT;

ADAPTIVE IMMUNITY; ALLOIMMUNITY; ANTIINFLAMMATORY ACTIVITY; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL INTERACTION; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; DENDRITIC CELL; END STAGE RENAL DISEASE; ENDOTHELIUM CELL; GENE EXPRESSION PROFILING; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSURVEILLANCE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIFE EXPECTANCY; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; NONHUMAN; PROTEIN SECRETION; QUALITY OF LIFE; REGULATORY T LYMPHOCYTE; REVIEW; SURVIVAL RATE; TREATMENT RESPONSE; UBIQUITINATION; ANIMAL; FIBROSIS; KIDNEY; KIDNEY FAILURE, CHRONIC; PATHOLOGY; PROCEDURES;

ANIMALS; FIBROSIS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS;

EID: 84908012942     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2014.06.002     Document Type: Review

References (88)

1. Levey A.S., Coresh J. Chronic kidney disease. Lancet 2012, 379:165-180.
2. Turin T.C., Tonelli M., Manns B.J., et al. Lifetime risk of ESRD. J Am Soc Nephrol 2012, 23:1569-1578.
3. Lamb K.E., Lodhi S., Meier-Kriesche H.U. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011, 11:450-462.
4. DiPersio J.F. Diabetic stem-cell "mobilopathy". N Engl J Med 2011, 365:2536-2538.
5. Pittenger M.F., Mackay A.M., Beck S.C., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
6. Friedenstein A.J., Deriglasova U.F., Kulagina N.N., et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol 1974, 2:83-92.
7. Horwitz E.M., Le Blanc K., Dominici M., et al. Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement. Cytotherapy 2005, 7:393-395.
8. Ahmad T., Mukherjee S., Pattnaik B., et al. Miro1 regulates intercellular mitochondrial transport and enhances mesenchymal stem cell rescue efficacy. EMBO J 2014, 33:994-1010.
9. Crisan M., Yap S., Casteilla L., et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008, 3:301-313.
10. Pelekanos R.A., Li J., Gongora M., et al. Comprehensive transcriptome and immunophenotype analysis of renal and cardiac MSC-like populations supports strong congruence with bone marrow MSC despite maintenance of distinct identities. Stem Cell Res 2012, 8:58-73.
11. Bruno S., Bussolati B., Grange C., et al. Isolation and characterization of resident mesenchymal stem cells in human glomeruli. Stem Cells Dev 2009, 18:867-880.
12. Lee O.K., Kuo T.K., Chen W.M., Lee K.D., Hsieh S.L., Chen T.H. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood 2004, 103:1669-1675.
13. Pierdomenico L., Bonsi L., Calvitti M., et al. Multipotent mesenchymal stem cells with immunosuppressive activity can be easily isolated from dental pulp. Transplantation 2005, 80:836-842.
14. Zuk P.A., Zhu M., Ashjian P., et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002, 13:4279-4295.
15. Salem H.K., Thiemermann C. Mesenchymal stromal cells: current understanding and clinical status. Stem Cells 2010, 28:585-596.
16. English K., Wood K.J. Mesenchymal stromal cells in transplantation rejection and tolerance. Cold Spring Harb Perspect Med 2013, 3:a015560.
17. Bernardo M.E., Fibbe W.E. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell 2013, 13:392-402.
18. Melief S.M., Schrama E., Brugman M.H., et al. Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages. Stem Cells 2013, 31:1980-1991.
19. Ren G., Zhang L., Zhao X., et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008, 2:141-150.
20. Asari S., Itakura S., Ferreri K., et al. Mesenchymal stem cells suppress B-cell terminal differentiation. Exp Hematol 2009, 37:604-615.
21. Schena F., Gambini C., Gregorio A., et al. Interferon-gamma-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. Arthritis Rheum 2010, 62:2776-2786.
22. Youd M., Blickarz C., Woodworth L., et al. Allogeneic mesenchymal stem cells do not protect NZBxNZW F1 mice from developing lupus disease. Clin Exp Immunol 2010, 161:176-186.
23. Spaggiari G.M., Capobianco A., Abdelrazik H., Becchetti F., Mingari M.C., Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 2008, 111:1327-1333.
24. Bianco P., Cao X., Frenette P.S., et al. The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nat Med 2013, 19:35-42.
25. Lee S., Huen S., Nishio H., et al. Distinct macrophage phenotypes contribute to kidney injury and repair. J Am Soc Nephrol 2011, 22:317-326.
26. Zhang M.Z., Yao B., Yang S., et al. CSF-1 signaling mediates recovery from acute kidney injury. J Clin Invest 2012, 122:4519-4532.
27. Li W., Ren G., Huang Y., et al. Mesenchymal stem cells: a double-edged sword in regulating immune responses. Cell Death Differ 2012, 19:1505-1513.
28. Khairoun M., van der Pol P., de Vries D.K., et al. Renal ischemia-reperfusion induces a dysbalance of angiopoietins, accompanied by proliferation of pericytes and fibrosis. Am J Physiol Renal Physiol 2013, 305:F901-10.
29. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473:298-307.
30. Carrion B., Kong Y.P., Kaigler D., Putnam A.J. Bone marrow-derived mesenchymal stem cells enhance angiogenesis via their alpha6beta1 integrin receptor. Exp Cell Res 2013, 319:2964-2976.
31. Humphreys B.D., Lin S.L., Kobayashi A., et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 2010, 176:85-97.
32. Wang Y., He J., Pei X., Zhao W. Systematic review and meta-analysis of mesenchymal stem/stromal cells therapy for impaired renal function in small animal models. Nephrology 2013, 18:201-208.
33. Casiraghi F., Azzollini N., Todeschini M., et al. Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation. Am J Transplant 2012, 12:2373-2383.
34. Ge W., et al. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation 2010, 90:1312-1320.
35. Togel F., Zhang P., Hu Z., Westenfelder C. VEGF is a mediator of the renoprotective effects of multipotent marrow stromal cells in acute kidney injury. J Cell Mol Med 2009, 13:2109-2114.
36. Casiraghi F., Azzollini N., Todeschini M., et al. Insulin-like growth factor-1 sustains stem cell mediated renal repair. J Am Soc Nephrol 2007, 18:2921-2928.
37. Bonventre J.V. Microvesicles from mesenchymal stromal cells protect against acute kidney injury. J Am Soc Nephrol 2009, 20:927-928.
38. Tomasoni S., Longaretti L., Rota C., et al. Transfer of growth factor receptor mRNA via exosomes unravels the regenerative effect of mesenchymal stem cells. Stem Cells Dev 2013, 22:772-780.
39. Bruno S., Grange C., Deregibus M.C., et al. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol 2009, 20:1053-1067.
40. Eggenhofer E., Benseler V., Kroemer A., et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol 2012, 3:297.
41. Dominici M., Le Blanc K., Mueller I., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
42. Fibbe W.E., Dazzi F., LeBlanc K. MSCs: science and trials. Nat Med 2013, 19:812-813.
43. Suntharalingam G., Perry M.R., Ward S., et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006, 355:1018-1028.
44. Seok J., Warren H.S., Cuenca A.G., et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A 2013, 110:3507-3512.
45. Perico N., Casiraghi F., Introna M., et al. Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol 2011, 6:412-422.
46. Perico N., Casiraghi F., Gotti E., et al. Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. Transpl Int 2013, 26:867-878.
47. Tan J., Wu W., Xu X., et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA 2012, 307:1169-1177.
48. Ekberg H., Tedesco-Silva H., Demirbas A., et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007, 357:2562-2575.
49. Reinders M.E., de Fijter J.W., Roelofs H., et al. Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study. Stem Cells Transl Med 2013, 2:107-111.
50. Peng Y., Ke M., Xu L., et al. Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. Transplantation 2013, 95:161-168.
51. Ge W., Jiang J., Baroja M.L., et al. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant 2009, 9:1760-1772.
52. Streitz M., Miloud T., Kapinsky M., et al. Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study. Transpl Res 2013, 2:17.
53. Reinders M.E., Leuning D.G., de Fijter J.W., Hoogduijn M.J., Rabelink T.J. Mesenchymal stromal cell therapy for cardio renal disorders. Curr Pharm Des 2014, 20:2412-2429.
54. Horn P., Bokermann G., Cholewa D., et al. Impact of individual platelet lysates on isolation and growth of human mesenchymal stromal cells. Cytotherapy 2010, 12:888-898.
55. Horn P., Bokermann G., Cholewa D., et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol 2008, 181:3933-3946.
56. Bartholomew A., Sturgeon C., Siatskas M., et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002, 30:42-48.
57. Zhou H.P., Yi D.H., Yu S.Q., et al. Administration of donor-derived mesenchymal stem cells can prolong the survival of rat cardiac allograft. Transplant Proc 2006, 38:3046-3051.
58. Franquesa M., Herrero E., Torras J., et al. Mesenchymal stem cell therapy prevents interstitial fibrosis and tubular atrophy in a rat kidney allograft model. Stem Cells Dev 2012, 21:3125-3135.
59. Roemeling-van Rhijn K.M., Korevaar S.S., Lievers E., et al. Human bone marrow-and adipose tissue-derived mesenchymal stromal cells are immunosuppressive in vitro and in a humanized allograft rejection model. J Stem Cell Res Ther 2013, Suppl 6. 001. doi: 10.4172/2157-7633.S6-001.
60. Houtgraaf J.H., den Dekker W.K., van Dalen B.M., et al. First experience in humans using adipose tissue-derived regenerative cells in the treatment of patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 2012, 59:539-540.
61. Bongso A., Fong C.Y. The therapeutic potential, challenges and future clinical directions of stem cells from the Wharton's jelly of the human umbilical cord. Stem Cell Rev 2013, 9:226-240.
62. Zhou S., Greenberger J.S., Epperly M.W., et al. Age-related intrinsic changes in human bone-marrow-derived mesenchymal stem cells and their differentiation to osteoblasts. Aging Cell 2008, 7:335-343.
63. Vaes B., Van't Hof W., Deans R., Pinxteren J. Application of MultiStem((R)) allogeneic cells for immunomodulatory therapy: clinical progress and pre-clinical challenges in prophylaxis for graft versus host disease. Front Immunol 2012, 3:345.
64. Griffin M.D., Ryan A.E., Alagesan S., Lohan P., Treacy O., Ritter T. Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far?. Immunol Cell Biol 2013, 91:40-51.
65. Seifert M., Stolk M., Polenz D., Volk H.D. Detrimental effects of rat mesenchymal stromal cell pre-treatment in a model of acute kidney rejection. Front Immunol 2012, 3:202.
66. Inoue S., Popp F.C., Koehl G.E., et al. Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation 2006, 81:1589-1595.
67. Everly M.J., Rebellato L.M., Haisch C.E., et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation 2013, 95:410-417.
68. Loupy A., Hill G.S., Jordan S.C. The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol 2012, 8:348-357.
69. Freitas M.C., Rebellato L.M., Ozawa M., et al. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation 2013, 95:1113-1119.
70. Reinders M.E., Roemeling-van Rhijn M., Khairoun M., et al. Bone marrow-derived mesenchymal stromal cells from patients with end-stage renal disease are suitable for autologous therapy. Cytotherapy 2013, 15(6):663-672.
71. Roemeling-van Rhijn M., Reinders M.E., de Klein A., et al. Mesenchymal stem cells derived from adipose tissue are not affected by renal disease. Kidney Int 2012, 82:748-758.
72. Noh H., Yu M.R., Kim H.J., et al. Uremia induces functional incompetence of bone marrow-derived stromal cells. Nephrol Dial Transplant 2012, 27:218-225.
73. Kramann R., Couson S.K., Neuss S., et al. Exposure to uremic serum induces a procalcific phenotype in human mesenchymal stem cells. Arterioscler Thromb Vasc Biol 2011, 31:e45-e54.
74. Le Blanc K., Frassoni F., Ball L., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
75. Koc O.N., Gerson S.L., Cooper B.W., et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000, 18:307-316.
76. Available: Accessed May 20, 2014. http://www.clinicaltrials.gov.
77. Hare J.M., Fishman J.E., Gerstenblith G., et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 2012, 308:2369-2379.
78. Schuleri K.H., Feigenbaum G.S., Centola M., et al. Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy. Eur Heart J 2009, 30:2722-2732.
79. Sanganalmath S.K., Bolli R. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res 2013, 113:810-834.
80. Ball L.M., Bernardo M.E., Roelofs H., et al. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. Br J Haematol 2013, 163:501-509.
81. Krampera M., Galipeau J., Shi Y., Tarte K., Sensebe L., Therapy MSCCotISfC Immunological characterization of multipotent mesenchymal stromal cells-The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy 2013, 15:1054-1061.
82. Tarte K., Gaillard J., Lataillade J.J., et al. Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood 2010, 115:1549-1553.
83. Available Accessed May 20, 2014. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000295.jsp&mid=WC0b01ac058007f4bb.
84. Available Accessed May 20, 2014. http://www.lonza.com/about-lonza/media-center/news/2013/130220-ipsc-e.aspx.
85. Xia Y., Nivet E., Sancho-Martinez I., et al. Directed differentiation of human pluripotent cells to ureteric bud kidney progenitor-like cells. Nat Cell Biol 2013, 15:1507-1515.
86. Takasato M., Er P.X., Becroft M., et al. Directing human embryonic stem cell differentiation towards a renal lineage generates a self-organizing kidney. Nat Cell Biol 2014, 16:118-126.
87. Olson S.D., Pollock K., Kambal A., et al. Genetically engineered mesenchymal stem cells as a proposed therapeutic for Huntington's disease. Mol Neurobiol 2012, 45:87-98.
88. Moon H.H., Joo M.K., Mok H., et al. MSC-based VEGF gene therapy in rat myocardial infarction model using facial amphipathic bile acid-conjugated polyethyleneimine. Biomaterials 2014, 35:1744-1754.